IP Library › Granted Patent US 12,336,937
Granted Patent B2
US 12,336,937 · App. 17/109,063 · Granted Jun 24, 2025

Multi-wavelength phototherapy devices, systems, and methods for the non-invasive treatment of damaged or diseased tissue

Inventors: Clark E Tedford (Poulsbo, WA); Scott DeLapp (San Diego, CA); Scott Bradley (San Marcos, CA)
Assignee: LumiThera, Inc.
A61F9/0079A61N5/0613A61N5/0616A61N5/062A61N5/0622A61N5/0624A61F2009/00863A61N2005/0643A61N2005/0648A61N2005/0651A61N2005/0659A61N2005/0662A61N5/067
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,336,937
App. No.
17/109,063
Granted
Jun 24, 2025
Kind
B2
Abstract

Provided are multi-wavelength phototherapy devices, systems and methods for the treatment of a disorder or disease, including multi-wavelength low level light therapy (“PBM”), in particular to multi-wavelength PBM and other phototherapy systems and methods for improving functionality in and/or restoring functionality to a cell and/or tissue through the coordinated and targeted delivery to the cell or tissue of two or more doses of light having distinct wavelengths, wherein the two or more doses of light, when delivered in a coordinated fashion, can stimulate the activity of two or more light sensitive factors that, when activated, provide and/or enhance a desired target cell functionality. Ophthalmic phototherapy devices, systems, and treatment methods to expose an eye to selected multi-wavelengths of light to promote the healing of damaged or diseased eye tissue. The devices include a housing having an interior; an eyepiece disposed on the housing and configured and arranged for placement of an eye of the patient adjacent the eyepiece; a first light source producing a first light beam having a first therapeutic wavelength and disposed within the housing; a second light source producing a second light beam having a second therapeutic wavelength and disposed within the housing, where the second therapeutic wavelength differs from the first therapeutic wavelength by at least 25 nm.

Claims (58)

1. A wearable device for delivery of photobiomodulation (PBM) to retinal tissue of an eye of a patient, the wearable device comprising:

a frame comprising a front piece and at least one affixation element attached to the front piece, wherein the front piece is configured to be positioned in front of the eye of the patient;

at least one first light source disposed within or on the at least one affixation element and configured to produce light in a first light beam having a first PBM wavelength comprising near infrared (NIR) light;

at least one second light source disposed within or on the at least one affixation element and configured to produce light in a second light beam having a second PBM wavelength,

wherein the second PBM wavelength differs from the first PBM wavelength by at least 25 nm, and

wherein at least a portion of each of the first light beam and the second light beam is directed toward the front piece of the frame;

a diffuser configured to homogenize the light in the first light beam or the second light beam, or in both the first light beam and the second light beam, such that an energy density profile of the light is evenly distributed among a range of emission angles; and

at least one light directing element disposed within or on the front piece of the frame and configured to receive and redirect the at least a portion of each of the first light beam having the first PBM wavelength and the second light beam having the second PBM wavelength toward the retinal tissue of the eye of the patient when the patient is wearing the wearable device.

2. The wearable device of claim 1 , further comprising at least one third light source disposed within or on the affixation element and configured to produce light in a third light beam having a third PBM wavelength,

wherein the third PBM wavelength differs from the first PBM wavelength and the second PBM wavelength by at least 25 nm,

wherein the diffuser is further configured to homogenize the light in the third light beam, and

wherein at least a portion of the third light beam is directed toward the front piece of the frame to be redirected by the at least one light directing element toward the retinal tissue of the eye of the patient.

3. The wearable device of claim 2 , wherein the first PBM wavelength is in a range from 800 to 900 nm, the second PBM wavelength is in a range from 600 to 700 nm, and the third PBM wavelength is in a range from 550 to 650 nm.

4. The wearable device of claim 1 , wherein the first PBM wavelength is in a range from 800 to 900 nm and the second PBM wavelength is in a range from 600 to 700 nm.

5. The wearable device of claim 1 , wherein the first PBM wavelength is in a range from 800 to 900 nm and the second PBM wavelength is in a range from 550 to 650 nm.

6. The wearable device of claim 1 , wherein the first light beam has a PBM wavelength that produces a first therapeutic effect and the second light beam has a PBM wavelength that produces a second therapeutic effect that differs from the first therapeutic effect.

7. The wearable device of claim 1 , wherein the at least one affixation element comprises an earpiece and the at least one light directing element comprises at least one reflector,

wherein the at least one first light source and the at least one second light source are disposed within or on the earpiece and arranged to direct the light in the first and second light beams toward the at least one reflector, and

wherein the at least one reflector is arranged to redirect at least a portion of the light in the first and second light beams toward the eye of the patient.

8. The wearable device of claim 7 , wherein the at least one reflector comprises the diffuser configured to homogenize the light in the first and second light beams.

9. The wearable device of claim 7 , wherein the at least one reflector is partially transparent.

10. The wearable device of claim 1 , further comprising:

a spatial light modulator disposed within or on the frame and positioned to receive the first and second light beams and to modulate the light in the first and second light beams to generate a modulated light beam;

wherein the light directing element is configured to receive the modulated light beam and redirect at least a portion of the modulated light beam toward the eye of the patient when the patient is wearing the wearable device.

11. The wearable device of claim 1 , further comprising an internal controller within or on the frame and coupled to the at least one first and second light sources to control production of the first and second light beams, wherein the internal controller is communicatively coupled to an external controller that is usable to program the internal controller to control operation of the at least one first and second light sources according to a predetermined treatment regimen.

12. The wearable device of claim 11 , wherein the predetermined treatment regimen includes a set of activation times or periods during which each of the at least one first and second light sources is in an emitting state and a set of inactivation times or periods during which each of the at least one first and second light sources is in a non-emitting state.

13. The wearable device of claim 1 , wherein the first and second light beams deliver light to the retinal tissue of the eye of the patient in at least two doses, wherein the first light beam in a first dose is predetermined to stimulate a first activity in the retinal tissue, and the second light beam in a second dose is predetermined to stimulate a second activity in the retinal tissue, wherein the second activity differs from the first activity.

14. The wearable device of claim 1 , wherein the light in each of the first and second light beams has an irradiance at the retinal tissue that facilitates healing and/or reverses or slows disease progression in the retinal tissue.

15. A wearable device for delivery of photobiomodulation (PBM) to retinal tissue of an eye of a patient, the wearable device comprising:

a frame comprising a front piece and at least one affixation element attached to the front piece, wherein the front piece is configured to be positioned in front of the eye of the patient;

at least one light source disposed within or on the frame and configured to produce light in a light beam having a PBM wavelength;

a diffuser configured to homogenize the light in the light beam, producing a uniform distribution of energy in the light;

a spatial light modulator disposed within or on the frame and positioned to receive the light beam and to modulate the light in the light beam to generate a modulated light beam; and

a light directing element within or on the frame to receive the modulated light beam and to redirect at least a portion of the modulated light beam toward the retinal tissue of the eye of the patient when the patient is wearing the wearable device.

16. The wearable device of claim 15 , wherein the light directing element is a prism or a waveguide.

17. The wearable device of claim 15 , wherein the at least one light source is disposed within or on the at least one affixation element, and the light directing element is disposed within or on the front piece of the frame.

18. The wearable device of claim 15 , wherein the at least one light source comprises:

at least one first light source configured to produce light in a first light beam having a first PBM wavelength; and

at least one second light source configured to produce light in a second light beam having a second PBM wavelength, wherein the second PBM wavelength differs from the first PBM wavelength by at least 25 nm,

wherein the diffuser is configured to homogenize the light in the first light beam and/or the second light beam.

19. The wearable device of claim 18 , wherein the at least one light source further comprises:

at least one third light source configured to produce light in a third light beam having a third PBM wavelength, wherein the diffuser is further configured to homogenize the light in the third light beam;

wherein the third PBM wavelength differs from the first and second wavelengths by at least 25 nm.

20. A method of providing PBM to retinal tissue of a patient wearing the wearable device of claim 1 , the method comprising:

placing the wearable device on the patient;

directing the light of the first PBM wavelength to the retinal tissue of the eye of the patient to produce a first therapeutic effect; and

directing the light of the second PBM wavelength from the wearable device to the retinal tissue of the eye of the patient to produce a second therapeutic effect that differs from the first therapeutic effect.

21. The method of claim 20 , wherein the light of at least one of the first PBM wavelength or the second PBM wavelength is diffused through an eyelid of the patient before the light reaches the retinal tissue of the eye of the patient.

22. The method of claim 20 , wherein the light of the first PBM wavelength and the light of the second PBM wavelength is diffused through an eyelid of the patient before the light reaches the retinal tissue of the eye of the patient.

23. The method of claim 22 , wherein the directing the light comprises sequentially directing the light of the first PBM wavelength and the light of the second PBM wavelength from the wearable device to the retinal tissue of the eye of the patient.

24. The method of claim 22 , wherein the directing the light comprises simultaneously directing the light of the first PBM wavelength and light of the second PBM wavelength from the wearable device to the retinal tissue of the eye of the patient.

25. A wearable device for delivery of photobiomodulation (PBM) to retinal tissue of an eye of a patient, the wearable device comprising:

a frame comprising a front piece and at least one affixation element attached to the front piece;

at least one first light source producing a first light beam having a first PBM wavelength comprising near infrared (NIR) light and disposed within or on the frame;

at least one second light source producing a second light beam having a second PBM wavelength and disposed within or on the frame, wherein the second PBM wavelength is in a range from 600 to 700 nm or is in a range from 550 to 650 nm; and

a diffuser adapted to homogenize the light in the first light beam or the second light beam, or in both the first light beam and the second light beam, reducing non-uniformities in an energy density profile of the light,

wherein at least a portion of each of the first light beam having the first PBM wavelength and the second light beam having the second PBM wavelength is directed toward the retinal tissue of the eye of the patient when the patient is wearing the wearable device.

26. The wearable device of claim 25 , wherein the at least one affixation element comprises an earpiece and the frame further comprises at least one reflector disposed on the front piece, wherein the at least one first light source and the at least one second light source are disposed on the earpiece and arranged to direct the light in the first and second light beams toward the at least one reflector, wherein the at least one reflector is arranged to redirect at least a portion of the light in the first and second light beams toward the eye of the patient.

Continuity (6)
Continuation 14956366 · Dec 1, 2015
Continuation In Part PCTUS2015049261 · Sep 9, 2015
Provisional Application 62048211 · Sep 9, 2014
Provisional Application 62048187 · Sep 9, 2014
Provisional Application 62048182 · Sep 9, 2014
Related Publication 20210315736A1 · Oct 14, 2021
References Cited (238)
US 4057054A · Giannone · 1977 [cited by applicant]
US 4917486A · Raven et al. · 1990 [cited by applicant]
US 4930504A · Diamantopoulos et al. · 1990 [cited by applicant]
US 4940323A · Downing · 1990 [cited by applicant]
US 5259380A · Mendes et al. · 1993 [cited by applicant]
US 5290272A · Burstein et al. · 1994 [cited by applicant]
US 5426662A · Mefferd et al. · 1995 [cited by applicant]
US 5447527A · Waldman · 1995 [cited by applicant]
US 5520679A · Lin · 1996 [cited by applicant]
US 5533997A · Ruiz · 1996 [cited by applicant]
US 5683436A · Mendes et al. · 1997 [cited by applicant]
US 5755752A · Segal · 1998 [cited by applicant]
US 5766233A · Thiberg · 1998 [cited by applicant]
US 5904678A · Pop · 1999 [cited by applicant]
US 5964749A · Eckhouse et al. · 1999 [cited by applicant]
US 5997141A · Heacock · 1999 [cited by applicant]
US 6019754A · Kawesch · 2000 [cited by applicant]
US 6235014B1 · Abe et al. · 2001 [cited by applicant]
US 6238424B1 · Thiberg · 2001 [cited by applicant]
US 6274614B1 · Richter et al. · 2001 [cited by applicant]
US 6283956B1 · McDaniel · 2001 [cited by applicant]
US 6287296B1 · Seiler et al. · 2001 [cited by applicant]
US 6319273B1 · Chen et al. · 2001 [cited by applicant]
US 6349001B1 · Spitzer · 2002 [cited by applicant]
US 6350275B1 · Vreman et al. · 2002 [cited by applicant]
US 6387089B1 · Kreindel et al. · 2002 [cited by applicant]
US 6443976B1 · Flower et al. · 2002 [cited by applicant]
US 6443978B1 · Zharov · 2002 [cited by applicant]
US 6471716B1 · Pecukonis · 2002 [cited by applicant]
US 6537302B1 · Thiberg · 2003 [cited by applicant]
US 6537304B1 · Oron · 2003 [cited by applicant]
US 6607522B1 · Hamblin et al. · 2003 [cited by applicant]
US 6676655B2 · McDaniel · 2004 [cited by applicant]
US 6677366B2 · Richter et al. · 2004 [cited by applicant]
US 6689124B1 · Thiberg · 2004 [cited by applicant]
US 6811563B2 · Savage, Jr. et al. · 2004 [cited by applicant]
US 6887260B1 · McDaniel · 2005 [cited by applicant]
US 6918922B2 · Oron · 2005 [cited by applicant]
US 7014639B2 · Walneck et al. · 2006 [cited by applicant]
US 7118563B2 · Weckwerth et al. · 2006 [cited by applicant]
US 7303578B2 · De Taboada et al. · 2007 [cited by applicant]
US 7309348B2 · Streeter et al. · 2007 [cited by applicant]
US 7354432B2 · Eells et al. · 2008 [cited by applicant]
US 7479136B2 · Dotson · 2009 [cited by applicant]
US 7534255B1 · Streeter et al. · 2009 [cited by applicant]
US 7695504B2 · Anders et al. · 2010 [cited by applicant]
US 7744590B2 · Eells et al. · 2010 [cited by applicant]
US 7914523B2 · Barolet et al. · 2011 [cited by applicant]
US 7919094B2 · Schwaeble et al. · 2011 [cited by applicant]
US 8025687B2 · Streeter et al. · 2011 [cited by applicant]
US 8106038B2 · Margaron et al. · 2012 [cited by applicant]
US 8167921B2 · Streeter et al. · 2012 [cited by applicant]
US 8308784B2 · Streeter et al. · 2012 [cited by applicant]
US 8471967B2 · Miao et al. · 2013 [cited by applicant]
US 8508830B1 · Wang · 2013 [cited by applicant]
US 8582209B1 · Amirparviz · 2013 [cited by applicant]
US 8705177B1 · Miao · 2014 [cited by applicant]
US 8956396B1 · Friend · 2015 [cited by examiner]
US 9192780B2 · McDaniel · 2015 [cited by applicant]
US 10219944B2 · Tedford et al. · 2019 [cited by applicant]
US 10286180B2 · Colbaugh · 2019 [cited by applicant]
US 10596037B2 · Tedford et al. · 2020 [cited by applicant]
US 10881550B2 · Tedford et al. · 2021 [cited by applicant]
US 20020004673A1 · Cho et al. · 2002 [cited by applicant]
US 20020087207A1 · Cho et al. · 2002 [cited by applicant]
US 20020173778A1 · Knopp et al. · 2002 [cited by applicant]
US 20020198575A1 · Sullivan · 2002 [cited by applicant]
US 20030004556A1 · McDaniel · 2003 [cited by applicant]
US 20030050674A1 · Joshi · 2003 [cited by applicant]
US 20030093135A1 · Denton et al. · 2003 [cited by applicant]
US 20040002694A1 · Pawlowski et al. · 2004 [cited by applicant]
US 20040008523A1 · Butler · 2004 [cited by applicant]
US 20040030370A1 · Lytle · 2004 [cited by applicant]
US 20040116909A1 · Neuberger et al. · 2004 [cited by applicant]
US 20040158234A1 · Previn et al. · 2004 [cited by applicant]
US 20040193234A1 · Butler · 2004 [cited by applicant]
US 20040215293A1 · Eells et al. · 2004 [cited by applicant]
US 20040243198A1 · Heacock et al. · 2004 [cited by applicant]
US 20050015120A1 · Seibel et al. · 2005 [cited by applicant]
US 20050055015A1 · Buzawa · 2005 [cited by applicant]
US 20050149150A1 · McDaniel · 2005 [cited by applicant]
US 20050159793A1 · Streeter · 2005 [cited by applicant]
US 20050203592A1 · Teichert · 2005 [cited by applicant]
US 20050234527A1 · Slatkine · 2005 [cited by applicant]
US 20050240168A1 · Neuberger et al. · 2005 [cited by applicant]
US 20060004306A1 · Altshuler et al. · 2006 [cited by applicant]
US 20060184214A1 · McDaniel · 2006 [cited by applicant]
US 20060235493A1 · Dotson · 2006 [cited by applicant]
US 20070123844A1 · Henry · 2007 [cited by applicant]
US 20070244526A1 · Zaghetto et al. · 2007 [cited by applicant]
US 20070252951A1 · Hammer et al. · 2007 [cited by applicant]
US 20080009839A1 · Dotson · 2008 [cited by applicant]
US 20080009922A1 · Bille · 2008 [cited by applicant]
US 20080015553A1 · Zacharias · 2008 [cited by applicant]
US 20080058783A1 · Altshuler et al. · 2008 [cited by applicant]
US 20080234668A1 · Linnik et al. · 2008 [cited by applicant]
US 20080246920A1 · Buczek · 2008 [cited by applicant]
US 20080269730A1 · Dotson · 2008 [cited by applicant]
US 20080269849A1 · Lewis · 2008 [cited by applicant]
US 20090062779A1 · Rizoiu et al. · 2009 [cited by applicant]
US 20090262308A1 · Ogawa · 2009 [cited by applicant]
US 20090309959A1 · Iwai et al. · 2009 [cited by applicant]
US 20100010592A1 · De Taboada et al. · 2010 [cited by applicant]
US 20100010594A1 · De Taboada et al. · 2010 [cited by applicant]
US 20100016783A1 · Bourke, Jr. et al. · 2010 [cited by applicant]
US 20100079356A1 · Hoellwarth · 2010 [cited by applicant]
US 20100079865A1 · Saarikko et al. · 2010 [cited by applicant]
US 20110098692A1 · Shazly et al. · 2011 [cited by applicant]
US 20110237999A1 · Muller et al. · 2011 [cited by applicant]
US 20110257467A1 · Clegg et al. · 2011 [cited by applicant]
US 20130009853A1 · Hesselink et al. · 2013 [cited by applicant]
US 20130023966A1 · Depfenhart et al. · 2013 [cited by applicant]
US 20130033756A1 · Spitzer et al. · 2013 [cited by applicant]
US 20130053929A1 · Colbaugh · 2013 [cited by applicant]
US 20130060187A1 · Friedman et al. · 2013 [cited by applicant]
US 20130069985A1 · Wong et al. · 2013 [cited by applicant]
US 20130079759A1 · Dotson et al. · 2013 [cited by applicant]
US 20130088413A1 · Raffle et al. · 2013 [cited by applicant]
US 20130100362A1 · Saeedi et al. · 2013 [cited by applicant]
US 20130103014A1 · Gooding et al. · 2013 [cited by applicant]
US 20130204235A1 · Palanker · 2013 [cited by applicant]
US 20130258270A1 · Cazalet et al. · 2013 [cited by applicant]
US 20140049451A1 · Sugiyama · 2014 [cited by examiner]
US 20140128941A1 · Williams · 2014 [cited by examiner]
US 20140171624A1 · Krammer et al. · 2014 [cited by applicant]
US 20140194957A1 · Rubinfeld et al. · 2014 [cited by applicant]
US 20140277292A1 · Steel · 2014 [cited by examiner]
US 20150231408A1 · Williams et al. · 2015 [cited by applicant]
US 20150234207A1 · Koifman · 2015 [cited by applicant]
US 20160067087A1 · Tedford et al. · 2016 [cited by applicant]
CN 2453879Y · 2001 [cited by applicant]
CN 101896144A · 2010 [cited by applicant]
CN 201710538U · 2011 [cited by applicant]
CN 102271758A · 2011 [cited by applicant]
CN 102905750A · 2013 [cited by applicant]
CN 202682583U · 2013 [cited by applicant]
EP 1829496A2 · 2007 [cited by applicant]
EP 2532747A1 · 2012 [cited by applicant]
JP 2003516830A · 2003 [cited by applicant]
JP 2006101940A · 2006 [cited by applicant]
JP 2009525141A · 2009 [cited by applicant]
JP 2013521988A · 2013 [cited by applicant]
JP 2013235256A · 2013 [cited by applicant]
WO 0143825A1 · 2001 [cited by applicant]
WO 2004105873A1 · 2004 [cited by applicant]
WO 2005025672A1 · 2005 [cited by applicant]
WO 2007092349A2 · 2007 [cited by applicant]
WO 2008009062A1 · 2008 [cited by applicant]
WO 2008131343A1 · 2008 [cited by applicant]
WO 2009059730A1 · 2009 [cited by applicant]
WO 2011116306A2 · 2011 [cited by applicant]
WO 2012070054A1 · 2012 [cited by applicant]
WO 2012167944A1 · 2012 [cited by applicant]
WO 2013062654A1 · 2013 [cited by applicant]
WO 2013148713A1 · 2013 [cited by applicant]
WO 2014118571A1 · 2014 [cited by applicant]
WO 2016040534A1 · 2016 [cited by applicant]
“Product Development,” LumiThera, archived Aug. 20, 2014, URL=https://web.archive.org/web/20140820101900/https://www.lumithera.com:80/products/, download date Mar. 5, 2018. (2 pages). [cited by applicant]
Barnstable et al., “Neuroprotective and antiangiogenic actions of PEDF in the eye: molecular targets and therapeutic potential,” [cited by applicant]
Begum et al., “Treatment with 670 nm Light Up Regulates Cytochrome C Oxidase Expression and Reduces Inflammation in an Age-Related Macular Degeneration Model,” [cited by applicant]
Belevich et al., “Exploring the proton pump mechanism of cytochrome c oxidase in real time,” [cited by applicant]
Belevich et al., “Initiation of the proton pump of cytochrome c oxidase,” [cited by applicant]
Belevich et al., “Proton-coupled electron transfer drives the proton pump of cytochrome c oxidase,” [cited by applicant]
Brodeur, FLIP4, URL=www.spatrends.com/index, download date Mar. 1, 2005, 1 page. [cited by applicant]
Chung et al., “The Nuts and Bolts of Low-level Laser (Light) Therapy,” [cited by applicant]
Damico et al., “New approaches and potential treatments for dry age-related macular degeneration,” [cited by applicant]
Darlot et al., “Near-Infrared Light is Neuroprotective in a Monkey Model of Parkinson Disease,” [cited by applicant]
De Taboada et al., “Transcranial Laser Therapy Attenuates Amyloid-β Peptide Neuropathology in Amyloid-β Protein Precursor Transgenic Mice,” [cited by applicant]
Eells et al., “Mitochondrial signal transduction in accelerated wound and retinal healing by near-infrared light therapy,” [cited by applicant]
English Translation of Office Action, mailed Sep. 3, 2019, for CN Application No. 201580055435.9, 14 pages. [cited by applicant]
English Translation of Office Action, dated Aug. 4, 2020, for Japanese Application No. 2019-201176, 3 pages. [cited by applicant]
Final Office Action, mailed Mar. 12, 2008, for U.S. Appl. No. 11/106,416, Dotson, “Ophthalmic Phototherapy Device and Associated Treatment Method,” 8 pages. [cited by applicant]
Funk et al., “Outer Segments of Retinal Photoreceptors—A Review in the Light of Novel Findings,” [cited by applicant]
Gkotsi et al., “Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP,” [cited by applicant]
Glaser et al., “Retinal Pigment Epithelial Cells Release Inhibitors of Neovascularization,” [cited by applicant]
Gorbikova et al., “The proton donor for O-O bond scission by cytochrome c oxidase,” [cited by applicant]
Grossman et al., “780 nm Low Power Diode Laser Irradiation Stimulates Proliferation of Keratinocyte Cultures: Involvement of Reactive Oxygen Species,” [cited by applicant]
Hamblin et al., “Mechanisms of Low Light Therapy,” [cited by applicant]
Hashmi et al., “Role of Low-Level Laser Therapy in Neurorehabilitation,” [cited by applicant]
Huang et al., “Biphasic Dose Response in Low Level Light Therapy—An Update,” [cited by applicant]
Huang et al., “Biphasic Dose Response in Low Level Light Therapy,” [cited by applicant]
Huang et al., “Low-level laser therapy (810 nm) protects primary cortical neurons against excitotoxicity in vitro,” [cited by applicant]
Huang et al., “Low-level laser therapy (LLLT) reduces oxidative stress in primary cortical neurons in vitro,” [cited by applicant]
International Organization for Standardization, “Ophthalmic instruments—Fundamental requirements and test methods—Part 2: Light hazard protection,” ISO 15004-2:2007(E) first edition, 2007, 42 pages. [cited by applicant]
Ivandic et al., “Low-Level Laser Therapy Improves Vision in Patients with Age-Related Macular Degeneration,” [cited by applicant]
Jasaitis et al., “Nanosecond electron tunneling between the hemes in cytochrome bo [cited by applicant]
Johnstone et al., “The potential of light therapy in Parkinson's disease,” [cited by applicant]
Johnstone et al., “Turning on Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's Disease,” [cited by applicant]
Kaila et al., “Prevention of leak in the proton pump of cytochrome c oxidase,” [cited by applicant]
Karu et al., “Exact Action Spectra for Cellular Responses Relevant to Phototherapy,” [cited by applicant]
Karu et al., “Cell Attachment to Extracellular Matrices in Modulated by Pulsed Radiation at 820 nm and Chemicals that Modify the Activity of Enzymes in the Plasma Membrane,” [cited by applicant]
Karu et al., “Cellular Effects of Low Power Laser Therapy Can be Mediated by Nitric Oxide,” [cited by applicant]
Karu et al., “Irradiation with He—Ne laser increases ATP level in cells cultivated in vitro,” [cited by applicant]
Karu, “Mechanisms of Low-Power Laser Light Action on Cellular Level,” [cited by applicant]
Kiire et al., “Subthreshold Micropulse Laser Therapy for Retinal Disorders,” [cited by applicant]
Laakso et al. (ed.), [cited by applicant]
Lane, “Power Games,” [cited by applicant]
Light Bioscience, “Gentlewaves LED Photomodulation Device,” downloaded from http://www.lightbioscience.com/led_device.html on Mar. 1, 2005, 1 page. [cited by applicant]
Lim et al., “Probe pressure effects on human skin diffuse reflectance and fluorescence spectroscopy measurements,” [cited by applicant]
Lisman et al., “Two Light-Induced Processes in the Photoreceptor Cells of Limulus Ventral Eye,” [cited by applicant]
Lubart et al., “Low Energy Laser Irradiation Promotes Cellular Redox Activity,” [cited by applicant]
LumiThera, “Photobiomodulation for eye diseases,” Selected Abstracts, Aug. 21, 2013. (24 pages). [cited by applicant]
Masha et al., “Low-Intensity Laser Irradiation at 660 nm Stimulates Transcription of Genes Involved in the Electron Transport Chain,” [cited by applicant]
Merry et al., “Treatment of dry Age-related Macular Degeneration with Photobiomodulation,” [cited by applicant]
Miller et al., “The Role of Retinal Pigment Epithelium on the Involution of Subretinal Neovascularization,” [cited by applicant]
Moro et al., “Photobiomodulation preserves behaviour and midbrain dopaminergic cells from MPTP toxicity: evidence from two mouse strains,” [cited by applicant]
Murphy et al., “Toward the discrimination of early melanoma from common and dysplastic nevus using fiber optic diffuse reflectance spectroscopy,” [cited by applicant]
Office Action, mailed Apr. 3, 2007, for U.S. Appl. No. 11/106,416, Dotson, “Ophthalmic Phototherapy Device and Associated Treatment Method,” 10 pages. [cited by applicant]
Office Action, mailed Feb. 25, 2008, for U.S. Appl. No. 11/858,351, Dotson, “Ophthalmic Phototherapy Treatment Method,” 12 pages. [cited by applicant]
Office Action, mailed Jan. 14, 2015, for U.S. Appl. No. 13/679,557, Dotson et al., “Ophthalmic Phototherapy Device and Associated Treatment Method,” 29 pages. [cited by applicant]
Office Action, mailed May 23, 2012, for U.S. Appl. No. 12/172,697, Dotson, “Ophthalmic Phototherapy Device and Associated Treatment Method,” 31 pages. [cited by applicant]
Office Action, mailed Jan. 30, 2020, for Mexican Application No. MX/a/2017/003012, 5 pages. (w/ English Translation). [cited by applicant]
Office Action, mailed Jan. 22, 2020, for New Zealand Application No. 730040, 6 pages. [cited by applicant]
Ogata et al., “Upregulation of Pigment Epithelium-Derived Factor after Laser Photocoagulation,” [cited by applicant]
Oron et al., “Low-level laser therapy applied transcranially to mice following traumatic brain injury significantly reduces long-term neurological deficits,” [cited by applicant]
Purushothuman et al., “Photobiomodulation with near infrared light mitigates Alzheimer's disease-related pathology in cerebral cortex—evidence from two transgenic mouse models,” [cited by applicant]
Riverside Facial Plastic Surgery and Sinus Center, Gentlewaves LED Photomodulation Fact Sheet, URL=http://www.riversideface.com/pages/gentlewaves.html, download date Mar. 9, 2015. (4 pages). [cited by applicant]
Robotic LED Skin Rejuvenation, FLIP4, URL=www.medspafinancing.com/new.html, download date Mar. 1, 2005, 1 page. [cited by applicant]
Rodríguez-Santana et al., “Laser Photobiomodulation as a Potential Multi-Hallmark Therapy for Age-Related Macular Degeneration,” [cited by applicant]
Rojas et al., “Low-level light therapy of the eye and brain,” [cited by applicant]
Sharma et al., “Dose Response Effects of 810 nm Laser Light on Mouse Primary Cortical Neurons,” [cited by applicant]
Siletsky et al., “Time-resolved single-turnover of ba [cited by applicant]
Sommer et al., “Biostimulatory Windows in Low-Intensity Laser Activation: Lasers, Scanners, and NASA's Light-Emitting Diode Array System,” [cited by applicant]
Tang et al., “Low-Intensity Far-Red Light Inhibits Early Lesions That Contribute to Diabetic Retinopathy: In Vivo and In Vitro,” [cited by applicant]
Tang et al., “Predicting complications with pretreatment testing in infantile haemangioma treated with oral propranolol,” [cited by applicant]
Tarita-Nistor et al., “Fixation Characteristics of Patients with Macular Degeneration Recorded with the MP-1 Microperimeter,” [cited by applicant]
Tata et al., “Laser therapy: A review of its mechanism of action and potential medical applications,” [cited by applicant]
Tedford et al., “Devices and Methods for Non-Invasive Multi-Wavelength Low Level Light Therapy for Ocular Treatments,” U.S. Appl. No. 62/048,182, filed Sep. 9, 2014, 51 pages. [cited by applicant]
Tedford et al., “Wearable Devices and Methods for Multi-Wavelength Low Level Light Therapy for Ocular Treatments,” U.S. Appl. No. 62/048,187, filed Sep. 9, 2014, 55 pages. [cited by applicant]
Tosk, “FDA Clears Gentle Waves: The First and Only Light Emitting Diode Device for the Treatment of Periorbital Wrinkles and Rhytids,” URL=http://www.drmcdaniel.com/fda-clears-gentlewaves, download date Mar. 9, 2015, 2 … [cited by applicant]
Tuchin, [cited by applicant]
Van Breugal et al., “Power Density and Exposure Time of He—Ne Laser Irradiation are More Important Than Total Energy Dose in Photo-Biomodulation of Human Fibroblasts In Vitro,” [cited by applicant]
Wells et al., “Biophysical mechanisms responsible for pulsed low-level laser excitation of neural tissue,” [cited by applicant]
Wong-Riley et al., “Photobiomodulation Directly Benefits Primary Neurons Functionally Inactivated by Toxins,” [cited by applicant]
Xuan et al., “Transcranial Low-Level Laser Therapy Improves Neurological Performance in Traumatic Brain Injury in Mice: Effect of Treatment Repetition Regimen,” [cited by applicant]
Anders, J. J. et al., “Low-Level Light/Laser Therapy Versus Photobiomodulation Therapy”, Photomedicine and Laser Surgery, vol. 33, No. 4, 2015, 2 pages. [cited by applicant]
Anders, J. J. et al., “Light-Emitting Diode Therapy and Low-Level Light Therapy are Photobiomodulation Therapy”, Photobiomodulation, Photomedicine, and Laser Surgery, vol. 37, No. 2, 2019, 3 pages. [cited by applicant]
Notice of Grounds for Preliminary Rejection for KR Application No. 10-2017-7009408, dated Nov. 29, 2022, 19 pages. [cited by applicant]
Cited By (6)
US 12,472,377 US 12,515,071 US 12,582,837 US 12,616,849 US 12,702,862 US 12,708,259